



**Atomwise**

# Bringing the Power of AI Drug Discovery to Academic Partners



**Andreia Lee, PhD.**

Partnering Executive  
Atomwise Inc.



**Better  
Medicines,  
Faster.**

**The leader in  
AI for drug  
discovery**

**1st**

to invent and use  
ConvNets for drug design

**\$174M+**

funding raised from  
prominent investors

**16B+**

small molecules in  
AtomNet

**700+**

drug discovery  
projects to date

**75%**

success across AIMS  
projects to date


**>100**

university partners  
worldwide\*

\***Partners include:** Stanford University, UCSD, Tulane University, Duke University, DNDi, University of Connecticut, University of Michigan, Bill & Melinda Gates Foundation

# Enormous Breadth of Applications




775 accepted projects to date across diverse diseases and application areas



- Ophthalmology
- Rheumatology
- Gastroenterology
- Hepatology
- Musculoskeletal
- Psychiatric
- Dermatology
- Hematology
- Agriculture/Antifungals
- CRISPR/Biodefense

# AIMS Awards Program

Artificial Intelligence Molecular Screen (AIMS) Awards provide valuable access to AI-based drug design to academic research labs.



★ **Upcoming Deadline: December 14<sup>th</sup>, 2020**



**Atomwise**



**Andreia Lee, PhD**

Partnering Executive,  
Atomwise Inc.

# Thank You!

Apply at:

[https://www.atomwise.com/  
aims-awards/](https://www.atomwise.com/aims-awards/)

Or contact us at

[academics@atomwise.com](mailto:academics@atomwise.com)